
Serum not making fresh vaccines amid surplus stock: Poonawalla
Serum Institute chief executive Adar Poonawalla, during a media event today, said the company has 200 million doses of vaccine stock available currently.
Serum Institute chief executive Adar Poonawalla, during a media event today, said the company has 200 million doses of vaccine stock available currently.
India has learned a lot and is in a stronger and better position to face any future wave or future pandemics, says Adar Poonawalla.
This multibagger stock has risen from ₹47 per share on February 1, 2021, to ₹283 level currently, after Adar Poonawalla-led Rising Sun Holdings acquired a 60% stake in the company.
Poonawalla says the biggest learning from the pandemic has been the realisation that one should not make forward looking predictions, as things have been changing fast with Covid-19
In an exclusive conversation with Fortune India, the executive chairperson of Biocon says India should immediately start mixing and matching existing vaccines to accelerate the vaccination drive.
The healthcare sector is dominated by family-run firms, some of which have come into prominence in the past year.
India’s vaccine giant faces the huge social responsibility of supply into the domestic market and a contractual demand for export of vaccines to foreign countries.
Bharat Biotech, founded by Krishna Ella and his wife Suchitra, has been at the forefront of making vaccines for a while. Yet it took a global pandemic for the spotlight to shine on the company.
As India battles the second wave of Covid-19, which has caused havoc across the country, healthcare companies have come to the fore as lifesavers, to ensure the attack of the virus is countered.
In an exclusive interview, U.K. Secretary of State for International Trade Elizabeth Truss talks about a potential Free Trade Agreement between India and the U.K., and further areas of collaboration.